BRCA2 and cancer: Identification of high-risk variants can also influence clinical decisions around patient treatment, including surgical options (i.e. choosing to have a total mastectomy instead of a wide local excision), while PARP inhibitors and cisplatin are key chemotherapeutic options for the treatment of cancers in patients carrying BRCA1 and BRCA2 pathogenic variants [3, 4].